Visit CURE at and CURE BioScience Explorations at

May 2011

New jobs listed with CURE:
Reimbursement Manager
Associate Scientist
Yale Licensing Associate
Executive Assistant in Madison
Research Associate in Branford
Scientist 1 (#3444) in Branford
Scientist 1 (#3509) in Branford

See more jobs
Events Column
5/18 5:00 pm - 7:30 pm
MIT Enterprise Forum of CT. "Women on the Leading Edge." New Haven Lawn Club, 193 Whitney Avenue, New Haven. more
5/25 2:30 pm - 7:00 pm
CT Venture Group and UConn present Scott Case of Startup America. "Connecting Opportunities: Driving Innovation through University Resources”. Student Union Theater & Ballrooms, UConn, Storrs more
Governor Malloy steps to the plate for bioscience
A message from CURE President Paul Pescatello

In a press conference May 17, Governor Dannel Malloy announced plans to invest $864 million in Connecticut bioscience. The funds will be used to reinvent the UConn Health Center, creating jobs, increasing access to health care, graduating more health care professionals, and attracting more research grants to the state.

"The proposal will help make Connecticut a leader in the bioscience industry," the Governor said.

The proposal will be paid for by a combination of current bonding, new bonding, private financing, and UConn Health Center resources.

Click here for Governor's press release.
Click here for financial details.
Click here for coverage in the Hartford Courant.

Governor Malloy's May 17 remarks reinforce what he said March 22 in Farmington to the audience of scientists, businesspeople, and investors assembled for the StemCONN 2011 stem cell symposium. He said then not only that he supports the state's continued role in stem cell research funding, but that he is determined to find ways to attract business investment to Connecticut.

"Connecticut is a small state," he told the StemCONN audience, "but it's always been at the forefront. "There's precious little we won't do to compete."  See CURE News report for further details.

It was great to see and hear the Governor at StemCONN, which showcased leading stem cell researchers from both within and without Connecticut. "The state’s investment in stem cell research ... is paying dividends ...," said Dr. Laura Grabel, chair of the StemCONN 2011 Organizing Committee and professor of biology at Wesleyan University. See CURE News report for further details.

As important as the scientific progress being made are the steps toward commercialization of stem cell research that are beginning to be taken. In introducing my StemCONN 2011 stem cell research commercialization panel, I underscored that "the insights and basic research findings of our universities are turned into therapies and cures only by industry. The hard and difficult work of developing and honing small and large molecule compounds and building and channeling stem cell lines into clinical treatments is in its way as hard and difficult as the basic early stage research about the fundamental mechanisms of stem cell action." See CURE News report for further details.

Governor Malloy's actions show his commitment to fostering an environment where the full potential of the Connecticut bioscience industry can be realized.

Paul R. Pescatello is President and CEO of CURE.

Link to Paul's other columns

More news from CT biopharma

Advanced BioHealing files for $200 million IPO
Led by chairman and CEO Kevin Rakin, the company develops cell-based regenerative medicines. Its signature product treats diabetic foot ulcers. Source

Advanced BioHealing cancels IPO in favor of sale
454 Life Sciences technology sequences sweet orange
Achillion announces positive results for hepatitis C drug
Illumina reports 2010 results
Alexion applies to treat aHUS in Europe and US
Amarin's AMR101 significantly reduces triglycerides in Phase 3 test
Amarin names Paul Huff chief commercial officer
Amgen announces results of Phase 3 trial of XGEVA™ for SRE
Bayer's regorafenib (gastrointetsinal tumors) is orphan drug
Biodel reformulates Linjeta™

Boehringer Ingelheim's Pradaxa®
now recommended for NVAF
Bristol-Myers Squibb PEG-Interferon Lamda results positive
Website launched for New Haven 'Downtown Crossing'
Manusri named SCP at Gilead Sciences in Barnford
Hartford Hospital allies with Central Connecticut Health Alliance

J&J's Tibotec starts global Phase 3 trials for hepatitis 3 drug
MannKind reports Q1 2011 results
MannKind End-of-Review meeting with FDA rescheduled
Mira Dx licenses breast cancer technology from Yale University
Pfizer Tafamidis slows TTR-FAO polyneuropathy disease
PhRMA: Record number of rare disease medicines in development
Butrans™ opioid analgesic now available from Purdue Pharma
Rib-X presents data re delafloxacin and radezolid
Rib-X presents data re its RX-04 development program
Rib-X announces Phase 2b trial re delafloxacin for MRSA
Ricerca in collaboration with Fulcrum Pharma

More news from CT universities & medical centers

New Cell and Genome Sciences building named lab of year
"The transformation of the University of Connecticut Health Center’s Cell and Genome Sciences Building in Farmington from a nondescript, late-1970s industrial research building into a state-of-the-art university research facility demonstrates how older buildings can find new life." Source

 UConn professors aim at improving care for Hartford patients
 Construction to begin on new nursing school wing
 Goldhamer wins grant from Muscular Dystrophy Association
 First births from frozen eggs at UConn Health Center
New post facilitates evidence-based health interventions
 Student program offers insights into underserved patients
 Report focuses on treatment for stroke-related blood clots
 UConn professor evaluates cigarette warnings
 Dr. Cato Laurencin elected to National Academy of Engineering
 New technologies test pharmacy students
 Dr. Gail Sullivan focuses on geriatric medicine
 High-tech video display helps with analyses
 Mechanical engineering professor investigate sickle-cell disease
 New post facilitates evidence-based health interventions

Yale scientists synthesize long-sought-after anticancer agent
A team of Yale University scientists has synthesized for the first time a chemical compound called lomaiviticin aglycon, leading to the development of a new class of molecules that appear to target and destroy cancer stem cells. Source

 Fewer multiple births in states with infertility insurance coverage
 Compulsive eating, substance dependence share brain patterns
 Yale and Gilead announce cancer research collaboration
 Obesity linked to infertility
 Weight gain linked to endometrial cancer risk
 The five hospital factors that affect heart attack survival
 Motorcycle crash study could influence helmet laws
 Gift launches new brain tumor program
 Combating childhood heart disease
 Scientists identify salmonella mechanism
 Researches identify gene mutations linked to high blood pressure
 Clues found to mystery of preterm delivery
 Boston Scientific $1.7 million gift to Yale School of Medicine
 New test for diagnosis of Turner Syndrome
 Records found of first-ever chemotherpay patient in 1942
 Bedside ultrasound becomes a reality
 Older patients fear heart medication side effects

Copyright 2011 © Connecticut United for Research Excellence. All rights reserved. Visit CURE at and CURE BioScience Explorations at
Click here for Archive of back issues.
Newsletter developed and edited by HarveyMalis Communications LLC, Guilford, Conn.

Managing Your Subscriptions
Click on the "Manage your subscription" link below and then on "Edit Your Profile." To subscribe to a publication, type a "y" in the box to the right of the publication name. To unsubscribe, leave the box blank.